Drug-induced arterial hypertension – a frequently ignored cause of secondary hypertension: a review

References

• Mancia G, Fagard L, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J. 2013;34:2159–2219.
   PubMed Web of Science ®Google Scholar
• Brem AS. Insights into glucocorticoid-associated hypertension. Am J Kidney Dis. 2001;37:1–10.
   PubMed Web of Science ®Google Scholar
• Woods JW. Oral contraceptives and hypertension. Hypertension 1988;11(suppl II):II-11–II-15.
   Web of Science ®Google Scholar
• Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996;94:483–489.
   PubMed Web of Science ®Google Scholar
• Mandel FP, Geola FL, Lu JK, et al. Biologic effects of various doses of ethinyl estradiol in postmenopausal women. Obstet Gynecol. 1982;59:673–679.
   PubMed Web of Science ®Google Scholar
• Bretza JA, Novey HS, Vaziri ND, et al. Hypertension: a complication of danazol therapy. Arch Intern Med. 1980;140:1379–1380.
   Google Scholar
• Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121:289–300.
   PubMed Web of Science ®Google Scholar
• Stollberger C, Finsterer J. Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences. South Med J. 2004;97:209–219.
   Web of Science ®Google Scholar
• Spindelegger CJ, Papageorgiou K, Grohmann R, et al. Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010. Int J Neuropsychopharmacol. 2015;18. DOI:10.1093/ijnp/pyu080
   Web of Science ®Google Scholar
• Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med. 2012;125:14–22.
   PubMed Web of Science ®Google Scholar
• Iancu MA, Diaconu C, Dediu G, et al. An analysis of hypertensive male patients addressed to a primary practice. J Hypertens. 2016;34, e-Suppl 1:e323.
   Web of Science ®Google Scholar
• Gorun GS, Dermengiu D, Curcă GC, et al. Toxicological drivers issues in “legal highs” use. Rom J Leg Med. 2010;XVIII (4): 271–279.
   Web of Science ®Google Scholar
• Izzo AA, Di Carlo G, Borrelli F, et al. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol. 2005;98:1–14.
   PubMed Web of Science ®Google Scholar
• Roche H, Hyman G, Nahas G. Hypertension and intravenous antidopaminergic drugs. N Engl J Med. 1985;312:1125–1126.
   PubMed Web of Science ®Google Scholar
• Sheridan C, Chandra P, Jacinto M, et al. Transient hypertension after high doses of metoclopramide. N Engl J Med. 1982;307:1346
   PubMed Web of Science ®Google Scholar
• Barjon P, Fourcade J, Mimran A, et al. Paroxysmal hypertension during L-dopa treatment in parkinsonism: a metabolic error or a pharmacological effect? Rev Eur Etud Clin Biol. 1972;17:187–192.
   Google Scholar
• Cain JW. Hypertension associated with oral administration of physostigmine in a patient with Alzheimer’s disease. Am J Psychiatry. 1986;143:910–912.
   Web of Science ®Google Scholar
• Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis. 2001;60:913–923.
   PubMed Web of Science ®Google Scholar
• Akpunonu BE, Mulrow PJ, Hoffman EA. Secondary hypertension: evaluation and treatment: thyrotoxicosis and hypertension. Dis Mon. 1996;42:689–703.
   Web of Science ®Google Scholar
• Liu LX, Rustgi AK. Cardiac myonecrosis in hypertensive crisis associated with monoamine oxidase inhibitor therapy. Am J Med. 1987;82:1060–1064.
   Web of Science ®Google Scholar
• Amsterdam JD, Garcia-Espana F, Fawcett J, et al. Blood pressure changes during short-term fluoxetine treatment. J Clin Psychopharmacol. 1999;19:9–14.
   PubMed Web of Science ®Google Scholar
• Kaufmann JS. Letter: Pheochromocytoma and tricyclic antidepressants). JAMA 1974;229:1282
   PubMed Web of Science ®Google Scholar
• Louie AK, Louie EK, Lannon RA. Systemic hypertension associated with tricyclic antidepressant treatment in patients with panic disorder. Am J Cardiol. 1992;70:1306–1309.
   Web of Science ®Google Scholar
• Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998;59:502–508.
   PubMed Web of Science ®Google Scholar
• Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;CD007893.
   Web of Science ®Google Scholar
• Cush JJ, Tugwell P, Weinblatt M, et al. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol. 1999;26:1176–1186.
   PubMed Web of Science ®Google Scholar
• Artz MA, Boots JM, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant. 2004;4:937–945.
   PubMed Web of Science ®Google Scholar
• Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens. 2010;23:460–468.
   PubMed Web of Science ®Google Scholar
• Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9:117–123.
   PubMed Web of Science ®Google Scholar
• Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med. 2008;358:95–97.
   PubMed Web of Science ®Google Scholar
• Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011;17:3841–3849.
   PubMed Web of Science ®Google Scholar
• Laragh JH. Renin-Guided Therapy. Clinical Hypertension Review Course Syllabus. New York, American Society of Hypertension. 2005; 353–355.
   Google Scholar
• Diaconu C, Nastasă A, Abdul Rehman Z, et al. A comparative analysis of the hypertension treatment depending on comorbidities: insights from clinical practice. J Hypertens 2016;34, e-Suppl 1:e320.
   Web of Science ®Google Scholar
• Diaconu C, Istratie B, Nastasă A, et al. An age-related comparison between comorbidities and treatment of hypertensive patients. J Hypertens 2016;34, e-Suppl 1:e321.
   Web of Science ®Google Scholar
• Oren S, Grossman E, Messerli FH, et al. High blood pressure: side effects of drugs, poisons, and food. Cardiol Clin. 1988;6:467–474.
   Google Scholar
• Lowenstein E. Sympathetic nervous system activation and hyperdynamic circulation associated with desflurane: not all isomers are created equal. Anesthesiology 1993;79:419–421.
   Web of Science ®Google Scholar
• Amaranath L, Zanettin GG, Bravo EL, et al. Atracurium and pheochromocytoma: a report of three cases. Anesth Analg. 1988;67:1127–1130.
   Web of Science ®Google Scholar
• Vaziri ND. Mechanisms of lead-induced hypertension and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2008;295:H454–H465.
   PubMed Web of Science ®Google Scholar
• Abhyankar LN, Jones MR, Guallar E, et al. Arsenic exposure and hypertension: a systematic review. Environ Health Perspect. 2012;120:494–500.
   PubMed Web of Science ®Google Scholar
• Houston MC. Role of mercury toxicity in hypertension, cardiovascular disease, and stroke. J Clin Hypertens (Greenwich). 2011;13:621–627.
   PubMed Web of Science ®Google Scholar
• Joyce DA, Gubbay SS. Arterial complications of migraine treatment with methysergide and parenteral ergotamine. Br Med J (Clin Res Ed). 1982;285:260–261.
   Web of Science ®Google Scholar
• Taylor GJ. Cohen Ergonovine-induced coronary artery spasm and myocardial infarction after normal delivery. Obstet Gynecol. 1985;66:821–822.
   PubMed Web of Science ®Google Scholar
• Bakht FR, Kirshon B, Baker T, et al. Postpartum cardiovascular complications after bromocriptine and cocaine use. Am J Obstet Gynecol. 1990;162:1065–1066.
   Web of Science ®Google Scholar
• Watson DL, Bhatia RK, Norman GS, et al. Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension? Obstet Gynecol. 1989;74:573–576.
   Web of Science ®Google Scholar